Ascendis Pharma A/S
ASNDNasdaq
$261.00
↑ +0.5%Jul 17 close · end-of-day
Price
1Y↑ +6.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
- CEO
- Jan M. Mikkelsen
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 1,189
- Website
- ascendispharma.com
Management & directors
- Smith Scott ThomasEVP & Chief Financial Officer
- Jensen Flemming SteenSee Remarks
Roles derived from SEC Form 4 filings.
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jul 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-02 | SMITH SCOTT THOMAS· EVP & Chief Financial Officer | Buy | 100 | $219.00 | $21,900.00 | filing |
| 2026-05-29 | SMITH SCOTT THOMAS· EVP & Chief Financial Officer | Buy | 250 | $223.32 | $55,830.00 | filing |
| 2026-05-29 | BIENAIME JEAN JACQUES | Buy | 200 | $223.76 | $44,752.00 | filing |
| 2026-05-29 | BIENAIME JEAN JACQUES | Buy | 200 | $222.30 | $44,460.00 | filing |
| 2026-05-29 | BIENAIME JEAN JACQUES | Buy | 100 | $223.50 | $22,350.00 | filing |
| 2026-05-26 | BIENAIME JEAN JACQUES | Buy | 200 | $239.37 | $47,873.50 | filing |
| 2026-05-26 | BIENAIME JEAN JACQUES | Buy | 200 | $236.24 | $47,247.00 | filing |
| 2026-05-11 | JENSEN FLEMMING STEEN· See Remarks | Sale | 19,460 | $238.49 | $4.6M | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.